This first-of-its-kind, non-systemic treatment approach has demonstrated the potential to accelerate cell movement to drive faster and more complete repair of wounds and burns, as well as regeneration of nerves, spinal cord and cardiac tissue.
Additionally, the company believes that the platform’s ability to decelerate cell motility has the potential to address other indications including cancer metastases and fibrosis.